Increasing value and reducing waste in stroke research

The Lancet Neurology

Volumn 16, Issue 5, 2017, Pages 399-408

  Berge, Eivind ^a,j   Al Shahi Salman, Rustam ^b,j   van der Worp, H Bart ^c   Stapf, Christian ^d,j   Sandercock, Peter ^b,j   Sprigg, Nikola ^e   Macleod, Malcolm R ^b   Kelly, Peter J ^f,g,j   Nederkoorn, Paul J ^h,j   Ford, Gary A ^i,j   Arnold, Marcel ^j   Diez Tejedor, Exuperio ^j   Jatuzis, Dalius ^j   Krieger, Derk W ^j   Weimar, Christian ^j  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; FUNDING; HUMAN; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; STRATEGIC PLANNING; EUROPE; MEDICAL RESEARCH; METHODOLOGY; STANDARDS;

BIOMEDICAL RESEARCH; EUROPE; HUMANS; RESEARCH DESIGN; STROKE;

EID: 85017399446     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30078-9     Document Type: Review

References (104)

1. 1 WHO. The top ten causes of death. Fact sheet no. 310, 2014, Word Health Organization, Geneva http://www.who.int/mediacentre/factsheets/fs310/en/ (accessed Jan 24, 2017).
2. 2 Krishnamurthi, RV, Feigin, VL, Forouzanfar, MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 1 (2013), e259–e281.
3. 3 Gustavsson, A, Svensson, M, Jacobi, F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21 (2011), 718–779.
4. 4 Heidenreich, PA, Trogdon, JG, Khavjou, OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123 (2011), 933–944.
5. 5 Johnston, SC, The 2008 William M. Feinberg lecture: prioritizing stroke research. Stroke 39 (2008), 3431–3436.
6. 6 Chambers, M, Hutton, J, Gladman, J, Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics 16 (1999), 577–593.
7. 7 Murray, CJ, Lauer, JA, Hutubessy, RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361 (2003), 717–725.
8. 8 Demaerschalk, BM, Hwang, HM, Leung, G, Cost analysis review of stroke centers, telestroke, and rt-PA. Am J Manag Care 16 (2010), 537–544.
9. 9 Ganesalingam, J, Pizzo, E, Morris, S, Sunderland, T, Ames, D, Lobotesis, K, Cost-utility analysis of mechanical thrombectomy using stent retrievers in acute ischemic stroke. Stroke 46 (2015), 2591–2598.
10. 10 Saka, O, Serra, V, Samyshkin, Y, McGuire, A, Wolfe, CC, Cost-effectiveness of stroke unit care followed by early supported discharge. Stroke 40 (2009), 24–29.
11. 11 Luengo-Fernandez, R, Leal, J, Gray, A, UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. BMJ Open, 5, 2015, e006648.
12. 12 Pendlebury, ST, Worldwide under-funding of stroke research. Int J Stroke 2 (2007), 80–84.
13. 13 Chalmers, I, Glasziou, P, Avoidable waste in the production and reporting of research evidence. Lancet 374 (2009), 86–89.
14. 14 Chalmers, I, Bracken, MB, Djulbegovic, B, et al. How to increase value and reduce waste when research priorities are set. Lancet 383 (2014), 156–165.
15. 15 Ioannidis, JP, Greenland, S, Hlatky, MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet 383 (2014), 166–175.
16. 16 Salman, RA-S, Beller, E, Kagan, J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet 383 (2014), 176–185.
17. 17 Chan, AW, Song, F, Vickers, A, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet 383 (2014), 257–266.
18. 18 Glasziou, P, Altman, DG, Bossuyt, P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 383 (2014), 267–276.
19. 19 Chabriat, H, Joutel, A, Dichgans, M, Tournier-Lasserve, E, Bousser, MG, Cadasil. Lancet Neurol 8 (2009), 643–653.
20. 20 Ioannidis, JP, Why most clinical research is not useful. PLoS Med, 13, 2016, e1002049.
21. 21 Hanney, SR, Gonzalez Block, MA, Building health research systems to achieve better health. Health Res Policy Syst, 4, 2006, 10.
22. 22 Chalmers, I, Atkinson, P, Fenton, M, Firkins, L, Crowe, S, Cowan, K, Tackling treatment uncertainties together: the evolution of the James Lind Initiative, 2003–2013. J R Soc Med 106 (2013), 482–491.
23. 23 Pollock, A, St George, B, Fenton, M, Firkins, L, Top 10 research priorities relating to life after stroke–consensus from stroke survivors, caregivers, and health professionals. Int J Stroke 9 (2014), 313–320.
24. 24 Oliver, S, Exploring lay perspectives in questions of effectiveness. Chalmers, I, Maynard, A, (eds.) Non-random reflections on health services research, 1997, BMJ Publishing Group, London, 272–291.
25. 25 Oliver, S, Users of health services: following their agenda. Hood, S, Mayall, B, Oliver, S, (eds.) Critical issues in social research, 1999, Open University Press, Buckingham, 139–153.
26. 26 McKevitt, C, Redfern, J, Mold, F, Wolfe, C, Qualitative studies of stroke: a systematic review. Stroke 35 (2004), 1499–1505.
27. 27 Mead, GE, Hsieh, CF, Lee, R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev, 11, 2012 CD009286.
28. 28 Mead, G, Hackett, ML, Lundstrom, E, Murray, V, Hankey, GJ, Dennis, M, The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials, 16, 2015, 369.
29. 29 Sacco, RL, Sandercock, P, Endres, M, et al. Review and prioritization of stroke research recommendations to address the mission of the World Stroke Organization: a call to action from the WSO Research Committee. Int J Stroke 10 (2015), 4–9.
30. 30 Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999), 2752–2758.
31. 31 van der Worp, HB, Howells, DW, et al. Can animal models of disease reliably inform human studies?. PLoS Med, 7, 2010, e1000245.
32. 32 Dirnagl, U, Hakim, A, Macleod, M, et al. A concerted appeal for international cooperation in preclinical stroke research. Stroke 44 (2013), 1754–1760.
33. 33 Jones, AP, Conroy, E, Williamson, PR, Clarke, M, Gamble, C, The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. BMC Med Res Methodol, 13, 2013, 50.
34. 34 Blommaert, J, Rationalizing the unreasonable: there are no good academics in the EU?. https://alternative-democracy-research.org/2015/06/10/rationalizing-the-unreasonable-there-are-no-good-academics-in-the-eu/ (accessed Jan 24, 2017).
35. 35 Ioannidis, JP, More time for research: fund people not projects. Nature 477 (2011), 529–531.
36. 36 Kilkenny, C, Browne, WJ, Cuthill, IC, Emerson, M, Altman, DG, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol, 8, 2010, e1000412.
37. 37 Macleod, MR, Fisher, M, O'Collins, V, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke 40 (2009), e50–e52.
38. 38 Minnerup, J, Zentsch, V, Schmidt, A, Fisher, M, Schabitz, WR, Methodological quality of experimental stroke studies published in the Stroke journal: time trends and effect of the basic science checklist. Stroke 47 (2016), 267–272.
39. 39 Lees, KR, Bath, PM, Schellinger, PD, et al. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 43 (2012), 1163–1170.
40. 40 Hachinski, V, Iadecola, C, Petersen, RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37 (2006), 2220–2241.
41. 41 Bath, PM, Gray, LJ, Collier, T, Pocock, S, Carpenter, J, Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 38 (2007), 1911–1915.
42. 42 Darbyshire, J, Sitzia, J, Cameron, D, et al. Extending the clinical research network approach to all of healthcare. Ann Oncol 22 (2011), vii36–vii43.
43. 43 Hicks, D, Wouters, P, Waltman, L, de Rijcke, S, Rafols, I, Bibliometrics: The Leiden Manifesto for research metrics. Nature 520 (2015), 429–431.
44. 44 Macleod, MR, Lawson, MA, Kyriakopoulou, A, et al. Risk of bias in reports of in vivo research: a focus for improvement. PLoS Biol, 13, 2015, e1002273.
45. 45 Armstrong, PW, Califf, RM, Data and safety monitoring boards: academic credit where credit is due?. JAMA 310 (2013), 1563–1564.
46. 46 The Academy of Medical Sciences. A new pathway for the regulation and governance of health research, 2011, The Academy of Medical Sciences, London.
47. 47 Berge, E, Ford, GA, Bath, PM, et al. Regulation and governance of multinational drug trials in stroke: barriers and possibilities. Int J Stroke 10 (2015), 425–428.
48. 48 van der Worp, HB, Macleod, MR, Bath, PM, et al. EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. Int J Stroke 9 (2014), 642–645.
49. 49 Sprigg, N, Robson, K, Bath, P, et al. Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: protocol for a randomized, placebo-controlled trial. Int J Stroke 11 (2016), 683–694.
50. 50 Shaw, L, Price, C, McLure, S, et al. Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): results from the pilot randomised controlled trial. Emerg Med J 31 (2014), 994–999.
51. 51 Germans, MR, Post, R, Coert, BA, Rinkel, GJ, Vandertop, WP, Verbaan, D, Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials, 14, 2013, 143.
52. 52 Anderson, CS, Robinson, T, Lindley, RI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med 374 (2016), 2313–2323.
53. 53 Bath, PM, Woodhouse, L, Scutt, P, et al. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 385 (2015), 617–628.
54. 54 Berkhemer, OA, Fransen, PS, Beumer, D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372 (2015), 11–20.
55. 55 Berge, E, Stapf, C, Al-Shahi, SR, et al. Methods to improve patient recruitment and retention in stroke trials. Int J Stroke 11 (2016), 663–676.
56. 56 European Commission. Regulation (EU) no 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, 2014, Publications Office of the European Union, Luxembourg.
57. 57 Lindblad, AS, Manukyan, Z, Purohit-Sheth, T, et al. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection. Clin Trials 11 (2014), 205–217.
58. 58 Food and Drug Administration. E6(R2) good clinical practice; international conference on harmonisation; draft guidance for industry; availability. A Notice by the Food and Drug Administration on 09/29/2015. Federal Register 80 (2015), 58492–58493.
59. 59 Clinical Trials Facilitation Groups. Guidance document for sponsors for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications. http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2013_06_CTFG_VHP.pdf (accessed Jan 24, 2017).
60. 60 Landis, S, Fisher, M, Why the United States needs a network for stroke clinical trials. Stroke 44 (2013), 1217–1218.
61. 61 Myles, PS, Williamson, E, Oakley, J, Forbes, A, Ethical and scientific considerations for patient enrollment into concurrent clinical trials. Trials, 15, 2014, 470.
62. 62 Treweek, S, Altman, DG, Bower, P, et al. Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platform. Trials, 16, 2015, 261.
63. 63 Smith, V, Clarke, M, Begley, C, Devane, D, SWAT-1: the effectiveness of a ‘site visit’ intervention on recruitment rates in a multi-centre randomised trial. Trials, 16, 2015, 211.
64. 64 Rick, J, Graffy, J, Knapp, P, et al. Systematic techniques for assisting recruitment to trials (START): study protocol for embedded, randomized controlled trials. Trials, 15, 2014, 407.
65. 65 Gibson, LM, Brazzelli, M, Thomas, BM, Sandercock, PA, A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full. Trials, 11, 2010, 43.
66. 66 Song, F, Parekh, S, Hooper, L, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess, 14, 2010, iii ix–iii, 1–193.
67. 67 The Lancet Neurology. Towards greater transparency in clinical trial reporting. Lancet Neurol, 15, 2016, 1295.
68. 68 Wieseler, B, Kerekes, MF, Vervoelgyi, V, McGauran, N, Kaiser, T, Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ, 344, 2012, d8141.
69. 69 Wieseler, B, Wolfram, N, McGauran, N, et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med, 10, 2013, e1001526.
70. 70 Shinton, R, Questions about authorisation of alteplase for ischaemic stroke. Lancet 384 (2014), 659–660.
71. 71 Bjork, BC, Welling, P, Laakso, M, Majlender, P, Hedlund, T, Gudnason, G, Open access to the scientific journal literature: situation 2009. PLoS One, 5, 2010, e11273.
72. 72 Rothwell, PM, Eliasziw, M, Gutnikov, SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361 (2003), 107–116.
73. 73 Rothwell, PM, Eliasziw, M, Gutnikov, SA, Warlow, CP, Barnett, HJ, Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 363 (2004), 915–924.
74. 74 Bonati, LH, Dobson, J, Algra, A, et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet 376 (2010), 1062–1073.
75. 75 Vahedi, K, Hofmeijer, J, Juettler, E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6 (2007), 215–222.
76. 76 Emberson, J, Lees, KR, Lyden, P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
77. 77 Goyal, M, Menon, BK, van Zwam, WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387 (2016), 1723–1731.
78. 78 Sandercock, P, Wardlaw, JM, Lindley, RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 379 (2012), 2352–2363.
79. 79 Cochrane, J, The third International Stroke Trial (IST-3)–an exemplary threaded publication?. http://blogs.biomedcentral.com/on-medicine/2012/05/25/the-third-international-stroke-trial-ist-3-an-exemplary-threaded-publication/, May 25, 2012 (accessed Jan 24, 2017).
80. 80 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995), 1581–1587.
81. 81 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349 (1997), 1569–1581.
82. 82 Longo, DL, Drazen, JM, Data sharing. N Engl J Med 374 (2016), 276–277.
83. 83 Taichman, DB, Backus, J, Baethge, C, et al. Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors. Lancet 387 (2016), e9–11.
84. 84 Antman, EM, Benjamin, EJ, Harrington, RA, et al. Acquisition, analysis, and sharing of data in 2015 and beyond: a survey of the landscape: a conference report from the American Heart Association Data Summit 2015. J Am Heart Assoc, 4, 2015, e002810.
85. 85 Haug, CJ, From patient to patient. Sharing the data from clinical trials. N Engl J Med 374 (2016), 2409–2411.
86. 86 Bierer, BE, Li, R, Barnes, M, Sim, I, A global, neutral platform for sharing trial data. N Engl J Med 374 (2016), 2411–2413.
87. 87 Patel, MR, Armstrong, PW, Bhatt, DL, et al. Sharing data from cardiovascular clinical trials. A proposal. N Engl J Med 375 (2016), 407–409.
88. 88 Bradford Hill, A, Reasons to write. BMJ, 2, 1965, 870.
89. 89 Sena, ES, van der Worp, HB, Bath, PM, Howells, DW, Macleod, MR, Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol, 8, 2010, e1000344.
90. 90 Liebeskind, DS, Kidwell, CS, Sayre, JW, Saver, JL, Evidence of publication bias in reporting acute stroke clinical trials. Neurology 67 (2006), 973–979.
91. 91 Whiteley, W, Chong, WL, Sengupta, A, Sandercock, P, Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40 (2009), e380–e389.
92. 92 Bath, FJ, Owen, VE, Bath, PM, Quality of full and final publications reporting acute stroke trials: a systematic review. Stroke 29 (1998), 2203–2210.
93. 93 Hoffmann, TC, Walker, MF, Langhorne, P, Eames, S, Thomas, E, Glasziou, P, What's in a name? The challenge of describing interventions in systematic reviews: analysis of a random sample of reviews of non-pharmacological stroke interventions. BMJ Open, 5, 2015, e009051.
94. 94 Heneghan, C, Goldacre, B, Mahtani, KR, Why clinical trial outcomes fail to translate into benefits for patients. Trials, 18, 2017, 122.
95. 95 Chan, AW, Tetzlaff, JM, Altman, DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 158 (2013), 200–207.
96. 96 EQUATOR network. Collaborative initiative involving 28 rehabilitation and disability journals. http://www.equator-network.org/2014/04/09/collaborative-initiative-involving-28-rehabilitation-and-disability-journals/, April 9, 2014 (accessed Jan 24, 2017).
97. 97 Hoffmann, TC, Glasziou, PP, Boutron, I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ, 348, 2014, g1687.
98. 98 van, VP, Hunter, SM, Donaldson, C, Pomeroy, V, Using the TIDieR checklist to standardize the description of a functional strength training intervention for the upper limb after stroke. J Neurol Phys Ther 40 (2016), 203–208.
99. 99 Schulz, KF, Altman, DG, Moher, D, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med, 8, 2010, 18.
100. 100 Turner, L, Shamseer, L, Altman, DG, Schulz, KF, Moher, D, Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev, 1, 2012, 60.
101. 101 Young, C, Horton, R, Putting clinical trials into context. Lancet 366 (2005), 107–108.
102. 102 Clark, S, Horton, R, Putting research into context—revisited. Lancet 376 (2010), 10–11.
103. 103 Kleinert, S, Benham, L, Collingridge, D, Summerskill, W, Horton, R, Further emphasis on research in context. Lancet 384 (2014), 2176–2177.
104. 104 Moher, D, Glasziou, P, Chalmers, I, et al. Increasing value and reducing waste in biomedical research: who's listening?. Lancet 387 (2016), 1573–1586.